Lapatinib ditosylate
Trade Name:
Tykerb
Manufacturer/Distributor:
GlaxoSmithKline
1-800-387-7374 (Medical Information); www.gsk.ca
Classification:
Antineoplastic agent
ATC Class:
L01XE07 Lapatinib
Status:
active
Notice of Compliance (yyyy/mm/dd):
2009/05/15
Date Marketed in Canada (yyyy/mm/dd):
2009/05
Presentation:
Tablet: 250 mg; DIN 02326442
Comments:
To be used in combination with capecitabine for treatment of patients with advanced or metastatic breast cancer (tumours overexpress HER2). Before starting lapatinib, patients should have already used taxanes, anthracycline and trastuzumab.
| Posted | Updated |
|---|---|
| 2010-01-26 09:34 | 2010-01-26 09:52 |
Back to:
Drug Product Listings 
